ArticleClinical epigenetics2025

FBLN2 promoter hypermethylation: a negative prognostic biomarker and anti-PD-1 response predictor in clear cell renal cell carcinoma via high-throughput CpG Island screening.

Wenfeng Liao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.